PD-1 Data Promise More Shake-ups In Melanoma Standard of Care
Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.
Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.